Modern crop biotechnology is being considered as a novel solution to the long-standing problems of food insecurity, low crop productivity, pest and disease prevalence, and micronutrient deficiency, particularly in developing and climate-vulnerable economies. Empirical evidence of its benefits...

The rapid advancement of technologies has opened a wide array of possibilities for us. Once engineering, which was limited to machines and other related abiotic segments, has seen some major developments, and now we can modify or genetically engineer living organisms. This new branch of science...

We examine how two highly successful new biotechnology firms (NBFs) source their most critical input -- scientific knowledge. We find that scientists at the two NBFs enter into large numbers of collaborative research efforts with scientists at other organizations, especially universities. Formal...

Population ecology models are elegant in form and adequate in describing aggregate data, but poor in telling stories and predicting the location of growth. Fundamentals models emphasizing the variables central to resource mobilization, such as intellectual human capital, can predict where and...

We examine the effects of university-based star scientists on three measures of performance for California biotechnology enterprises: the number of products in development, the number of products on the market, and changes in employment. The `star' concept which Zucker, Darby, and Brewer (1994)...

The purpose of this multiple case study is to explore the internationalization processes, patterns, and behaviours of BioTech firms producing a COVID-19 vaccine using the Biotechnology international new ventures (BioTech INVs) model as a conceptual framework. The sample consists of eight BioTech...

In this paper, we examine the determinants of control rights in technology strategic alliances between biotechnology firms and pharmaceutical corporations, as well as with other biotechnology firms. We undertake three clinical studies and an empirical analysis of 200 contracts. Consistent with...

Using detailed data on biotechnology in Japan, we find that identifiable collaborations" between particular university star scientists and firms have a large positive impact on firms'" research productivity, increasing the average firm's biotech patents by 34 percent development by 27 percent,...

Firms invest differentially in the intellectual human capital required to recognize, evaluate, and utilize technological breakthroughs occurring outside the firm. Such differential investment has been crucial in explaining which incumbent pharmaceutical firms have successfully transformed their...